PDS Biotechnology Corporation

NASDAQ: PDSB · Healthcare · Biotechnology

PublicHQ Princeton, NJ · MercerCIK 0001472091Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 24DQ —GM —SS 49

v0.1 · 35/100 weight · pillars only

↑ market scale, listing tenure · ↓ Piotroski F, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$34.5M

Employees

as of 2026-09-17

Market cap

$55.4M

as of 2026-09-17

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$34.5M-$34.5M2025

Operating income-$31.5M-$31.5M2025

Total assets$30.5M$30.5M2025

Liabilities$21.2M$21.2M2025

Equity$9.3M$9.3M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is PDS Biotechnology Corporation’s financial profile?

PDS Biotechnology Corporation earned -$34.5M in FY2025 net income.

Peers · Healthcare

Boundless Bio, Inc.——NDT Pharmaceuticals Inc.——MiNK Therapeutics, Inc.——MindWalk Holdings Corp.——Apollomics, Inc.——Dogwood Therapeutics, Inc.——

Neighbors

Mercer →

Bristol-Myers Squibb Company$48.2B85A Clearway Energy, Inc.$1.4B54D Essential Properties Realty Trust, Inc.$561.2M71B Miami International Holdings, Inc. $1.4B43D UroGen Pharma Ltd.$109.8M55C Kardigan, Inc.$0——

Key facts

CEOFrank K. Bedu-Addo

SectorHealthcare

IndustryBiotechnology

HeadquartersPrinceton, NJ

ExchangeNASDAQ: PDSB

Employees21

IPO date2015-09-30

Latest filings

8-K2026-09-14 8-K2026-09-08 8-K2026-09-04 8-K2026-08-25 8-K2026-08-19 8-K2026-08-14 10-Q2026-08-13 8-K2026-08-13

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.